BLOG

Ken Phares demystifies ICH Q14 & Q2(R2) guidelines with practical strategies for analytical procedure development, risk-based method design, and lifecycle management.

Discover how clinic-ready manufacturing and adaptive clinical trials streamline drug development, prevent delays, conserve your resources, and ensure safety, compliance, and efficiency.

The 2025 Year in Review highlights 30 years of drug development expertise, key milestones, events, resources, and innovations shaping early-phase research.

Brandon Ossont and Jennifer Lakritz share their first AALAS experiences, exploring scientific insights, networking, and professional growth in lab animal science.

Julie Forget reflects on the ACT Annual Meeting, highlighting cutting-edge toxicology research, gene therapy trends, and the strong sense of scientific community.

Altasciences conducted two drug-drug interaction studies to evaluate a novel cardiovascular therapy’s safety with clopidogrel and warfarin, ensuring safe co-administration.

Explore 30 years of CRO evolution, from preclinical roots to integrated, flexible partnerships—and how Altasciences is shaping the future of drug development.